Abstract
The combination MDCT and 111In-octreotide SPECT is useful in detection of the neuroendocrine tumor of unknown localization (presented as carcinoid-syndrome or Zollinger-Ellison syndrome) and assessment of the effect of somatostatine therapy or therapy using the somatostatin-analogon bearing the 111In or 90Y.
